.jpg)
.png)
I would like to wish everyone a Happy New Year! With the new year upon us and being more than halfway through my term as President, I wanted to thank the membership for the opportunity to provide a reminder of a few key initiatives of the NLA and make sure you complete your 2020 NLA checklist:
Article By:
President, National Lipid Association
Dean Emeritus, Weill Cornell Medicine
Provost for Medical Affairs Emeritus, Cornell University New York, NY
Diplomate, American Board of Clinical Lipidology
View the February 2020 Midwest quarterly e-newsletter by clicking here.
View the January 2020 NELA quarterly e-newsletter by clicking here.
View the December 2019 SELA E-Newsletter by clicking here.
View the December 2019 SWLA E-Newsletter by clicking here.
View the September 2019 NELA Board of Directors minutes by clicking here.
View the October 2019 Pacific quarterly e-newsletter by clicking here.
The NLA has published a scientific statement on the use of icosapent ethyl (IPE) in statin-treated patients that is based on the results of REDUCE-IT, the cardiovascular outcomes trial that examined the effects of IPE on major adverse cardiovascular events in high or very high-risk statin-treated patients with elevated triglycerides.
Article By:
Elizabeth Jackson CNS, CLS, FNLA
Membership Council Chair
New CLM-SAP Coming Soon The NLA is working on a new Complex Lipid Management Self-Assessment Program (CLM-SAP) on the 2018 Multisociety Guideline on the Management of Blood Cholesterol. The revised guideline emphasizes reducing risk of atherosclerotic cardiovascular disease (ASCVD) through lipid management. The CLM-SAP is designed to address practice gaps in lipid management utilizing the guidelines. This new online CLM-SAP module offers CME/CE credit and is free to all active NLA members.